Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ketotifen. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 5/20 | 1.00 |
| ▸ | DRD3 | P35462 | 7/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 5/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 5/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 5/20 | 1.00 |
| ▸ | DRD1 | P21728 | 5/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 4/20 | 1.00 |
| ▸ | HTR2A | P28223 | 4/20 | 1.00 |
| ▸ | HTR2C | P28335 | 4/20 | 1.00 |
| ▸ | LMNA | P02545 | 4/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 4/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 4/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 4/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 4/20 | 1.00 |
| ▸ | HTR3A | P46098 | 3/20 | 1.00 |
| ▸ | CHRM4 | P08173 | 3/20 | 1.00 |
| ▸ | CHRM5 | P08912 | 3/20 | 1.00 |
| ▸ | CHRM3 | P20309 | 3/20 | 1.00 |
| ▸ | HTR6 | P50406 | 3/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 3/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ketotifen SCHEMBL4436 | 1.00 | DRD3 (1.00) | DRD3HRH1CHRM2ADRA2ACHRM1 | |
| Ketotifen SCHEMBL29356083 | 1.00 | DRD3 (1.00) | DRD3HRH1CHRM2ADRA2ACHRM1 | |
| Ketotifen SCHEMBL1170804 | 0.99 | DRD3 (0.97) | DRD3HRH1CHRM2ADRA2ACHRM1 | |
| Ketotifen SCHEMBL3386047 | 0.99 | DRD3 (0.97) | DRD3HRH1CHRM2ADRA2ACHRM1 | |
| Ketotifen SCHEMBL1171289 | 0.99 | DRD3 (0.97) | DRD3HRH1CHRM2ADRA2ACHRM1 | |
| Ketotifen SCHEMBL28259803 | 0.97 | DRD3 (0.95) | DRD3HRH1CHRM2ADRA2ACHRM1 | |
| Ketotifen SCHEMBL1171294 | 0.95 | DRD3 (0.91) | DRD3HRH1CHRM2ADRA2ACHRM1 | |
| Ketotifen SCHEMBL9060252 | 0.94 | DRD3 (0.89) | DRD3HRH1CHRM2ADRA2ACHRM1 | |
| Ketotifen SCHEMBL5968240 | 0.93 | DRD3 (0.87) | DRD3HRH1CHRM2ADRA2ACHRM1 | |
| Ketotifen SCHEMBL1170677 | 0.91 | DRD3 (1.00) | DRD3HRH1CHRM2ADRA2ACHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120004265-A1 | Ophthalmic Compositions and Methods of Using the Same | WP PRISM INC. (N/K/A BAUSCH & LOMB HOLDINGS INC.) | 2012-01-05 | — | — | US | disclosed |
| CN-101087607-B | Ophthalmic compositions and methods of using the same | BAUSCH & LOMB | 2010-07-28 | — | — | CN | disclosed |
| EP-1845983-B1 | OPHTHALMIC COMPOSITIONS AND METHODS OF USING THE SAME | BAUSCH & LOMB (US) | 2010-04-07 | — | — | EP | disclosed |
| EP-1845983-A4 | OPHTHALMIC COMPOSITIONS AND METHODS OF USING THE SAME | BAUSCH & LOMB (US) | 2008-03-12 | — | — | EP | disclosed |
| CN-101087607-A | Ophthalmic compositions and methods of using the same | BAUSCH & LOMB (US) | 2007-12-12 | — | — | CN | disclosed |
| EP-1845983-A1 | OPHTHALMIC COMPOSITIONS AND METHODS OF USING THE SAME | BAUSCH & LOMB INCORPORATED (US) | 2007-10-24 | — | — | EP | disclosed |
| US-20060148899-A1 | Ophthalmic compositions and methods of using the same | BAUSCH & LOMB INCORPORATED | 2006-07-06 | — | — | US | disclosed |
| WO-2006047418-A1 | OPHTHALMIC COMPOSITIONS AND METHODS OF USING THE SAME | ALIMERA SCIENCES, INC. (US) | 2006-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004265-A1 | Ophthalmic Compositions and Methods of Using the Same | HRH2, HRH3, HRH1 | HRH1 3/4885DRD3 1308/4885CHRM2 764/4885 |
| US-20060148899-A1 | Ophthalmic compositions and methods of using the same | HRH2, HRH3, HRH1 | HRH1 3/4885DRD3 1308/4885CHRM2 764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.